INO · Inovio Pharmaceuticals, Inc.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx . This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event. About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology

Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase 2 adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute Study builds on the previously reported positive Phase 2 results involving INO-5401 in GBM , adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, in combination with cadonilimab, Akeso's first-in-class

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: American Association for Cancer Research Immuno-Oncology Conference (Los Angeles, CA) Date: Wednesday, February 18 Time: 7:30-10 PM PT, Poster Session A Poster Presentation : Treatment of RRP with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical response Oppenheimer 36th Annual Healthcare Life Sciences Conference (Virtual) Date: Wednesday, February 25 Time: 12:40 -1:10 PM ET Format: Fireside Chat Webcast: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/degYsHNqjq4UMJYMr4minN Festival of Biologics (San Diego, CA) Date: Wednesday, March 4 Time: